PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
36 hedge funds and large institutions have $6.64M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
93% more capital invested
Capital invested by funds: $3.45M → $6.64M (+$3.19M)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
3% more funds holding
Funds holding: 35 → 36 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.67M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.79M |
| 4 |
Millennium Management
New York
|
+$408K |
| 5 |
CC
Cannell & Co
New York
|
+$73.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$64.5K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$50K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$26.8K |
| 4 |
SGH
Schonfeld Group Holdings
Jericho,
New York
|
-$12K |
| 5 |
Renaissance Technologies
New York
|
-$10.5K |
PVCT Hedge Fund Activity: Q2 2015 in Review
36 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2015, worth a combined $6.64M — up 93% from $3.45M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PVCT positions and 3 closed out — a net gain of 2 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.67M. The largest seller was Virtu KCG Holdings, cutting an estimated $64.5K.
- 36 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2015, up from 35 in Q1 2015.
- Funds reported $6.64M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2015, up 93% quarter-over-quarter.
- 5 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2015 and 3 closed out, a net change of +2 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q2 2015 was Sabby Management, an estimated $2.67M added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q2 2015 was Virtu KCG Holdings, an estimated $64.5K sold.
Based on aggregated 13F filings for Q2 2015.